JP2001509797A - 慢性炎症性疾患のcm101/gbs毒素を用いる治療 - Google Patents
慢性炎症性疾患のcm101/gbs毒素を用いる治療Info
- Publication number
- JP2001509797A JP2001509797A JP53227598A JP53227598A JP2001509797A JP 2001509797 A JP2001509797 A JP 2001509797A JP 53227598 A JP53227598 A JP 53227598A JP 53227598 A JP53227598 A JP 53227598A JP 2001509797 A JP2001509797 A JP 2001509797A
- Authority
- JP
- Japan
- Prior art keywords
- toxin
- gbs
- patient
- disease
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.慢性炎症性疾患にかかっている患者を治療する方法であって、 B群のβ−溶血性連鎖状球菌(GBS)毒素を疾患の部位に、新しい血管の形成の 可能性を減少させるのに十分な量で患者に投与することを含む前記方法。 2.前記慢性疾患が脈管形成依存性である請求項1記載の方法。 3.前記慢性疾患が慢性関節リウマチ及び乾癬からなる群から選択される請求 項1の方法。 4.前記GBS毒素がCM101である請求項1の方法。 5.前記CM101が実質的に純粋である請求項4の方法。 6.前記CM101が少なくとも約90%の純度を有する請求項5の方法。 7.前記GBS毒素を非経口で投与する請求項1の方法。 8.前記GBS毒素を静脈内に投与する請求項7の方法。 9.前記患者が少なくとも生後4日である請求項1の方法。 10.前記患者が少なくとも生後7日である請求項9の方法。 11.請求項1の方法であって、前記治療を1週間から1ケ月の範囲内の間隔で 前記GBS毒素を患者に繰り返して投与することにより持続する方法。 12.前記間隔が7日〜2週間の範囲である請求項11の方法。 13.前記GBS毒素を1μg/kg〜100μg/kg体重のレベルで投与する請求項1 の方法。 14.前記GBS毒素を1μg/kg〜25μg/kg体重のレベルで投与する請求項13 の方法。 15.請求項1の方法であって、前記GBS毒素を前記GBS毒素の投 与後約8時間、患者の体の中の痛みを減少させるのに十分な量で投与する方法。 16.前記GBS毒素を体の関節内の腫張を減少させるのに十分な量で投与する請 求項1の方法。 17.前記GBS毒素を患者の滑膜組織内の脈管形成を抑制するのに十分な量で投 与する請求項1の方法。 18.前記疾患が乾癬であって、前記毒素が乾癬病害を減少させるのに十分な量 で投与する請求項3の方法。 19.脈管形成依存性である慢性炎症性疾患を治療する方法であって、病気の部 位に新しい血管の形成の可能性を減少させるが、傷の治癒を抑制しない化合物を 投与することを含む方法。 20.前記化合物がB群のβ−溶血性連鎖状球菌(GBS)毒素である請求項19の方 法。 21.前記GBS毒素がCM101である請求項20の方法。 22.前記CM101が実質的に純粋である請求項21の方法。 23.前記CM101が少なくとも約90%の純度を有する請求項22の方法。 24.患者の体内の慢性関節リウマチを治療する方法であって、B群のβ−溶血 性連鎖状球菌(GBS)毒素を慢性関節リウマチの兆候または症状を減少させるのに 十分な量で、患者に投与することを含む前記方法。 25.前記GBS毒素がCM101である請求項24の方法。 26.前記CM101が少なくとも約90%の純度を有する請求項25の方法。 27.患者の体内の乾癬を治療する方法であって、B群のβ−溶血性連鎖状球菌 (GBS)毒素を、乾癬の兆候または症状を減少させるのに十分な量で患者に投与す ることを含む前記方法。 28.前記GBS毒素がCM101である請求項27の方法。 29.前記CM101が少なくとも約90%の純度を有する請求項28の方法。 30.(a)医薬組成物であって、 (i)B群のβ−溶血性連鎖状球菌(GBS)毒素及び (ii)医薬として許容し得る担体を有する前記組成物、並びに (b)前記医薬組成物を慢性炎症性疾患の治療のために患者に投与するための使 用説明書、 を含む製品。 31.前記GBS毒素がCM101である請求項30の製品。 32.前記CM101が少なくとも約90%の純度を有する請求項31の製品。 33.前記使用説明書が、疾患の部位に新規な血管の形成の可能性を減少させる のに十分な量の前記医薬組成物の投与を記載する請求項30の製品。 34.前記使用説明書が慢性関節リウマチを治療するための前記医薬組成物の投 与を記載する請求項30の製品。 35.前記使用説明書が乾癬を治療するための前記医薬組成物の投与を記載する 請求項30の製品。 36.製品の製造方法であって、 (a)医薬組成物を包含する容器であって、前記医薬組成物が、 (i)B群のβ−溶血性連鎖状球菌(GBS)毒素及び (ii)医薬として許容し得る担体を含む、前記容器、並びに (b)慢性炎症性疾患にかかっている患者に前記医薬組成物を投与することによ り前記患者を治療するためのラベル化使用説明書を組み合せることを含む前記方 法。 37.前記GBS毒素がCM101である請求項36の方法。 38.前記CM101が少なくとも約90%の純度を有している請求項37の方法。 39.前記使用説明書が病気の部位に新しい血管の形成の可能性を減少させるの に十分な量の前記医薬組成物の投与を記載する請求項36の方法。 40.前記使用説明書が慢性関節リウマチの治療のための前記医薬組成物の投与 を記載する請求項36の方法。 41.前記使用説明書が乾癬の治療のための前記医薬組成物の投与を記載する請 求項36の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/790,989 | 1997-01-29 | ||
US08/790,989 US6028060A (en) | 1997-01-29 | 1997-01-29 | Treatment of chronic inflammatory diseases with CM101/GBS toxin |
PCT/US1998/001852 WO1998032452A1 (en) | 1997-01-29 | 1998-01-29 | Treatment of chronic inflammatory diseases with cm101/gbs toxin |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2001509797A true JP2001509797A (ja) | 2001-07-24 |
JP2001509797A5 JP2001509797A5 (ja) | 2005-10-06 |
Family
ID=25152333
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP53227598A Ceased JP2001509797A (ja) | 1997-01-29 | 1998-01-29 | 慢性炎症性疾患のcm101/gbs毒素を用いる治療 |
Country Status (12)
Country | Link |
---|---|
US (2) | US6028060A (ja) |
EP (1) | EP0981355B1 (ja) |
JP (1) | JP2001509797A (ja) |
CN (1) | CN1292759C (ja) |
AT (1) | ATE245991T1 (ja) |
AU (1) | AU6258898A (ja) |
DE (1) | DE69816807T2 (ja) |
DK (1) | DK0981355T3 (ja) |
ES (1) | ES2205450T3 (ja) |
HK (1) | HK1026372A1 (ja) |
PT (1) | PT981355E (ja) |
WO (1) | WO1998032452A1 (ja) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6028060A (en) * | 1997-01-29 | 2000-02-22 | Vanderbilt University | Treatment of chronic inflammatory diseases with CM101/GBS toxin |
US6803448B1 (en) | 1998-07-22 | 2004-10-12 | Vanderbilt University | GBS toxin receptor |
US8609614B2 (en) | 1998-07-22 | 2013-12-17 | Vanderbilt University | GBS toxin receptor compositions and methods of use |
US20030175713A1 (en) * | 2002-02-15 | 2003-09-18 | Clemens Sorg | Method for diagnosis of inflammatory diseases using CALGRANULIN C |
US9107864B2 (en) | 2004-06-07 | 2015-08-18 | Qu Biologics Inc. | Tissue targeted antigenic activation of the immune response to treat cancers |
EP3235506B1 (en) | 2010-07-26 | 2023-12-06 | Qu Biologics Inc. | Immunogenic anti-inflammatory compositions |
CN106456740B (zh) | 2014-05-02 | 2021-06-08 | Qu生物制药公司 | 抗微生物免疫调节 |
US11267854B2 (en) | 2016-07-20 | 2022-03-08 | Westfaelische Wilhelms-Universitaet Muenster | Complex-specific standardization of immunological methods for the quantification of S100A12 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS557014A (en) * | 1978-06-29 | 1980-01-18 | Chugai Pharmaceut Co Ltd | Antitumor agent and its preparation |
US4882317A (en) * | 1984-05-10 | 1989-11-21 | Merck & Co., Inc. | Covalently-modified bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers and methods of preparing such polysaccharides and conjugataes and of confirming covalency |
US5302386A (en) * | 1986-04-16 | 1994-04-12 | Brigham And Women's Hospital, Inc. | Bacterial antigens, antibodies, vaccines and methods of manufacture |
US4895838A (en) * | 1988-03-09 | 1990-01-23 | Trustees Of Boston University | Method for provoking angiogenesis by administration of angiogenically active oligosaccharides |
US5010062A (en) * | 1989-09-25 | 1991-04-23 | Vanderbilt University | Therapeutic agent and method of inhibiting vascularization of tumors |
US5225331A (en) * | 1991-04-25 | 1993-07-06 | National Research Council Of Canada | Immunoassay for detecting group b streptococcus |
US5382514A (en) * | 1992-03-31 | 1995-01-17 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | In vivo angiogenesis assay |
DE69233803D1 (de) * | 1992-10-28 | 2011-03-31 | Genentech Inc | Verwendung von vaskulären Endothelwachstumsfaktor-Antagonisten |
US5629327A (en) * | 1993-03-01 | 1997-05-13 | Childrens Hospital Medical Center Corp. | Methods and compositions for inhibition of angiogenesis |
CA2212370A1 (en) * | 1995-02-16 | 1996-08-22 | Moses Judah Folkman | Inhibition of angiogenesis using interleukin-12 |
WO1997041844A1 (en) * | 1996-05-09 | 1997-11-13 | Alcon Laboratories, Inc. | Combinations of angiostatic compounds |
US5811403A (en) * | 1996-09-30 | 1998-09-22 | Vanderbilt University | Polysaccharide toxin from Group B β-hemolytic Streptococcus (GBS) having improved purity |
US6028060A (en) * | 1997-01-29 | 2000-02-22 | Vanderbilt University | Treatment of chronic inflammatory diseases with CM101/GBS toxin |
-
1997
- 1997-01-29 US US08/790,989 patent/US6028060A/en not_active Expired - Lifetime
-
1998
- 1998-01-29 DE DE69816807T patent/DE69816807T2/de not_active Expired - Fee Related
- 1998-01-29 EP EP98904796A patent/EP0981355B1/en not_active Expired - Lifetime
- 1998-01-29 DK DK98904796T patent/DK0981355T3/da active
- 1998-01-29 ES ES98904796T patent/ES2205450T3/es not_active Expired - Lifetime
- 1998-01-29 JP JP53227598A patent/JP2001509797A/ja not_active Ceased
- 1998-01-29 AU AU62588/98A patent/AU6258898A/en not_active Abandoned
- 1998-01-29 WO PCT/US1998/001852 patent/WO1998032452A1/en active IP Right Grant
- 1998-01-29 AT AT98904796T patent/ATE245991T1/de not_active IP Right Cessation
- 1998-01-29 CN CNB988029057A patent/CN1292759C/zh not_active Expired - Fee Related
- 1998-01-29 PT PT98904796T patent/PT981355E/pt unknown
-
1999
- 1999-10-28 US US09/429,587 patent/US6476002B1/en not_active Expired - Fee Related
-
2000
- 2000-09-14 HK HK00105777A patent/HK1026372A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
EP0981355B1 (en) | 2003-07-30 |
US6476002B1 (en) | 2002-11-05 |
EP0981355A1 (en) | 2000-03-01 |
CN1251997A (zh) | 2000-05-03 |
HK1026372A1 (en) | 2000-12-15 |
CN1292759C (zh) | 2007-01-03 |
PT981355E (pt) | 2003-12-31 |
DE69816807T2 (de) | 2004-04-15 |
US6028060A (en) | 2000-02-22 |
ATE245991T1 (de) | 2003-08-15 |
AU6258898A (en) | 1998-08-18 |
ES2205450T3 (es) | 2004-05-01 |
DE69816807D1 (de) | 2003-09-04 |
WO1998032452A1 (en) | 1998-07-30 |
DK0981355T3 (da) | 2003-11-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Nishimura et al. | Attenuation of monosodium urate crystal‐induced arthritis in rabbits by a neutralizing antibody against interleukin‐8 | |
Spooner et al. | The role of tumor necrosis factor in sepsis | |
Marra et al. | Thrombin stimulates proliferation of liver fat-storing cells and expression of monocyte chemotactic protein-1: potential role in liver injury | |
Baker et al. | Control of established experimental allergic encephalomyelitis by inhibition of tumor necrosis factor (TNF) activity within the central nervous system using monoclonal antibodies and TNF receptor‐immunoglobulin fusion proteins | |
Callander et al. | Trousseau's syndrome. | |
Kozak et al. | TNF soluble receptor and antiserum against TNF enhance lipopolysaccharide fever in mice | |
CA2208673C (en) | Composition for inhibiting intimal hyperplasia using pdgf antagonists and heparin | |
JPH04500068A (ja) | 敗血症性ショックの治療および予防のための方法および組成物 | |
AU2010260585B2 (en) | Compositions and methods for treatment of Multiple Sclerosis | |
Kubes et al. | Rapid mast cell activation causes leukocyte-dependent and-independent permeability alterations | |
Sehic et al. | Complement reduction impairs the febrile response of guinea pigs to endotoxin | |
Beutler | The tumor necrosis factors: cachectin and lymphotoxin | |
JP2001509797A (ja) | 慢性炎症性疾患のcm101/gbs毒素を用いる治療 | |
Ogata et al. | An antagonist of platelet-activating factor suppresses endotoxin-induced tumor necrosis factor and mortality in mice pretreated with carrageenan | |
TAYLOR JR et al. | Finger gangrene caused by small artery occlusive disease | |
WO1995026193A1 (en) | Use of hyaluronic acid and forms to prevent arterial restenosis | |
Ogata et al. | Protective effects of a leukotriene inhibitor and a leukotriene antagonist on endotoxin-induced mortality in carrageenan-pretreated mice | |
TW202339731A (zh) | 用於治療進行性纖維化間質性肺病之新穎口服醫藥組合物及劑量療法 | |
Bourne | Cholera enterotoxin: failure of anti-inflammatory agents to prevent cyclic AMP accumulation | |
US20220184031A1 (en) | Dual antagonist of pgd2/dpr2 and thromboxane a2/tpr receptors and use for treatment of maladaptive immune response or thrombotic diathesis | |
Korzets et al. | Pefloxacin in adriamycin induced nephrotic syndrome in the rat. | |
Bresnahan et al. | Mesangial cell immune injury: effects of thromboxane receptor antagonism. | |
Taoka et al. | Antithrombin reduces compression-induced spinal cord injury in rats | |
Bloch et al. | Inhibition of immune complex-induced enteropathy by three different platelet-activating factor receptor antagonists | |
English | General practitioner excision of malignant melanoma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050128 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050128 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20081007 |
|
A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20090217 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090421 |